Advanced Search
CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
Citation: CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211

Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446

More Information
  • This study was to investigate the inhibitory effects of artemether in combination with etoposide on the proliferation and invasion ability of human small cell lung cancer cell line H446. H446 cells were treated with different concentrations of artemether or etoposide alone or their combination. The inhibitory effects on proliferation were detected by MTT assay, while cell cycle and apoptosis of H446 cells in each group were analyzed by flow cytometry using PI and Annexin V/PI-staining, respectively. The invasion capability of H446 cells in different groups was tested with matrigel-coated transwell. The results implicated that artemether or etoposide or their combination does inhibit proliferation of H446 cells dose-dependently. Artemether alone had little effect on the apoptosis of H446 cells while its combination with etoposide resulted in significantly apoptosis of H446 cells comparing with other groups(P< 0. 05). Etoposide blocked H446 progression markedly by arresting cell cycle in G2 phase with percentage of cells in G1 phase decreasing significantly while artemether alone or in combination with etoposide had little synergetic effect on cell cycle. Artemether or etoposite alone or their combination could dramatically inhibit the invasion ability of H446 cells.
  • [1]
    Byers LA,Rudin CM.Small cell lung cancer:where do we go from here[J]?Cancer,2015,121(5):664-672.
    [2]
    Asai N,Ohkuni Y,Kaneko N,et al.Relapsed small cell lung cancer:treatment options and latest developments[J].Ther Adv Med Oncol,2014,6(2):69-82.
    [3]
    Chaturvedi D,Goswami A,Saikia PP,et al.Artemisinin and its derivatives:a novel class of anti-malarial and anti-cancer agents[J].Chem Soc Rev,2010,39(2):435-454.
    [4]
    Chen T,Li M,Zhang R,et al.Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy[J].J Cell Mol Med,2009,13(7):1358-1370.
    [5]
    Gong Y,Gallis BM,Goodlett DR,et al.Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines[J].Anticancer Res,2013,33(1):123-132.
    [6]
    Lai HC,Singh NP,Sasaki T.Development of artemisinin compounds for cancer treatment[J].Invest New Drugs,2013,31(1):230-46.
    [7]
    Lu JJ, Chen SM, Zhang XW, et al. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J].Invest New Drugs,2011,29(6):1276-1283.
    [8]
    Das AK.Anticancer effect of antimalarial artemisinin compounds[J].Ann Med Health Sci Res,2015,5(2):93-102.
    [9]
    Guo T,Li HY,Yin XZ,et al. Mechanism of cyclodextrin inclusion of artemisinins in vacuum[J].J China Pharm Univ(中国药科大学学报),2010,41(6):513-519.
    [10]
    Simos D,Sajjady G,Sergi M,et al.Third-line chemotherapy in small-cell lung cancer:an international analysis[J].Clin Lung Cancer,2014,15(2):110-118.
    [11]
    Ho WE,Peh HY,Chan TK,et al.Artemisinins:pharmacological actions beyond anti-malarial[J].Pharmacol Ther,2014,142(1):126-139.

Catalog

    Article views PDF downloads Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return